将兵地那非治疗勃起功能障碍（ED）

阴茎勃起特适度障碍（ED）水痘来得同样应用于Vardenafil（魏地那非）进行化疗对ED药品Sildenafil（西地那非）和Vardenafil（魏地那非）进行同样比起实验，希望只能得到无种族歧视的结果。波士顿-2006年9年末20日，分析结果刊发在《适度期刊》上，同时在埃及卡拉奇开会的适度医学国际协会香港地区大会上刊发。这项分析并不独特，因为其信息来自一项关于PDE5（磷酸二脂酶5）抑制药品的实际上对比临床实验试验，该试验应用于PDE5抑制药品来化疗ED水痘。整个分析经过精心设计使得针对每种药品的种族歧视远超到最小化。这是一项随机、双盲、对角和实际上对比的临床实验试验，应用于西地那非和魏地那非化疗患ED、心血管结核病、冠心病和/或高血脂的男适度水痘，比起了二者的治果。结果表明在数个常以的有效适度常指标上魏地那非取得了生物学意味上的优势，在病人结果表明和同样适度的多个审计测试之前，魏地那非的表现并不比西地那非欠。共有1，057名男适度直接参与了这项分析，他们首先年终四个年末内施打一种药品，然后是一个年末内时长的缓冲期，接着再年终四个年末内施打另一种药品。病人会被说什么这样的疑虑：“总的来说，你来得喜欢应用于那种药品？”此外还有其他11个有关ED化疗的疑虑。利用按计划标准进行可用有效适度审计在分析之前也被应用于。信息显示38.9%的病人同样应用于魏地那非，而34.5%的病人愿意应用于西地那非（26.6%的病人无同样适度）。在阴茎勃起特适度，结果表明和相比之下结果表明特别，魏地那非特别是在优于西地那非。在阴茎勃起时插入硬度，阴茎勃起保持稳定时长，全程保持稳定和阴茎勃起信心特别，魏地那非也有来得高比例的阳适度反应。这项分析的共同作者，适度期刊的主编Irwin Goldstein 解释说：“该分析证明我们对PDE5抑制药品临床实验区别的阐释又前进了重要一步，称许了魏地那非化疗ED的。”目前有三种PDE5抑制药品可用于化疗ED，它们分别是西地那非，他远超那非和魏地那非。根据分析者的说法，所有这三种药品对一定范围内的人群都表现成有效适度和持续适度。来自实际上对比的临床实验实验信息（如本项分析）并不稀少，然而这样的分析结果会帮助临床实验外科医生对西地那非、魏地那非和他远超那非加以区别以选择最适于的药品供生殖病水痘应用于。背景知识：ED：阴茎勃起特适度障碍 Erectile dysfunction, ED是常指持续很难远超到或者保持稳定阴茎勃起以满足。ED比过去用的"阳萎"（Impotence）一词来得确切，因为高血压一词带有一定歧适度的贬义。ED可按其相对细分驭、之前、重三度，高血压仅常指重度的ED。70年代后由于阴茎勃起生理和病理分析的的发展，人们认识到固然以下几点确实可以引发ED，但对大多数男适度来说，ED与许多结核病（冠心病，心血管结核病，心血管结核病）、药品、外伤及手术等有关，因为阴茎勃起必要是海绵体中枢神经松弛，淋巴扩充张，血漂减少和微血管回漂情况严重等完整体内动力学全过程，在这一全过程之前，任何特适度障碍的成因可以细分： 器质适度ED 大脑适度因素：包括任何可能致使海绵体淋巴血漂减少的结核病，如：淋巴粥样硬化，淋巴损伤，淋巴狭窄，淋巴分漂及心特适度异常等，或杜绝微血管回漂合上必要的白膜、海绵窦内中枢神经减少所致的微血管勾。 大脑适度因素：之前枢、向外大脑结核病或损伤均可以致使阴茎勃起特适度障碍。 手术与外伤：大血管手术、癌症根治术、褐会阴直肠癌症根治术等手术及骨盆骨折、腰椎压缩适度骨折或驾跨伤，可以引发起有关的血管和大脑损伤，致使阴茎勃起特适度障碍。 内分泌疾患、慢适度病和长期施打某些药品也可以引发阴茎勃起特适度障碍。 本身结核病：如硬结综合症（Peyronie's disease）、弯曲畸形、严重背痛和包皮饲养炎。 焦虑适度ED 常指紧张、压力、意识分裂症、焦虑和夫妻感情不和等意识以下几点所造成的阴茎勃起特适度障碍。 混合适度ED 常指意识以下几点和器质适度成因共同致使的阴茎勃起特适度障碍。此外，由于器质适度ED未得到及时的化疗水痘焦虑压力渐增，畏惧失败，使ED化疗来得加趋于复杂。国内一组628例ED水痘成因分类的分析证明：焦虑适度占39%。器质适度为15.8%，混合适度占45.2%。PDE5药品PDE5是海绵体之前中枢神经细胞内第二信使NO-cGMP的分解酶。PDE5药品只能减少cGMP的浓度，增强海绵体中枢神经的松弛起着，并促进适度刺激诱导的阴茎勃起反应。PDE5药品类药品对ED化疗不具最广泛的有效适度和持续适度。因此，该类药品被来作低剂量化疗药品的详见标准。目前，该类药品包括三种：西地那非、魏地那非和他远超里斯非。西地那非在1998年，魏地那非和他里斯那非则是在2003年得到世界认证。在临床实验应用于以及临床实验对照分析之前发现，PDE5药品不具良好的持续适度和有效适度。在都可ED水痘之前，临床实验分析充分证实上述三种药品的有效适度。 Study shows men with ED for treatment with Vardenafil Preference trial for ED drugs Sildenafil vs. Vardenafil attempts unbiased results BOSTON -- September 20, 2006 ?Research published in The Journal of Sexual Medicine and presented at the 12th World Congress of the International Society for Sexual Medicine in Cairo, Egypt is unique in that the data is from a head to head trial of PDE5 inhibitors used to treat patients with erectile dysfunction (ED), designed to minimize bias toward either study drug. The study was a randomized, double-blind, crossover, head-to-head clinical trial that compared vardenafil and sildenafil treatment in men with ED and diabetes, hypertension, and/or hyperlipidemia. The results demonstrated that vardenafil achieved nominal statistical superiority over sildenafil for several frequently used efficacy measures, and non-inferiority of vardenafil to sildenafil as measured by various assessments of patient satisfaction and patient preference. A total of 1,057 men participated in the study, which involved treatment using each drug for four weeks, with a one-week washout period in between. Patients were asked: "Overall, which medication do you prefer?" along with 11 other preference questions relating to their ED treatment. Additional efficacy assessments using established scales were also used in ysis. Data showed that 38.9% preferred vardenafil compared to 34.5% sildenafil (26.6% had no preference). Vardenafil was significantly superior to sildenafil in terms of erectile function, intercourse satisfaction and overall satisfaction. There were also a significant higher percentage of positive responses for vardenafil with regards to erection hardness for penetration, maintenance of erection, maintenance until completion, and erection confidence. "This study represents an important step forward in our understanding of the clinical differences between PDE5 inhibitors, confirming the efficacy of vardenafil for men with erectile dysfunction," explains Irwin Goldstein, study co-author and Editor-in-Chief of The Journal of Sexual Medicine. There are currently three PDE5 inhibitors ailable to treat ED: sildenafil, tadalafil and vardenafil, all of which he previously demonstrated efficacy and tolerability in a range of patient populations, according to researchers. Data from head-to-head clinical trials, like this one, are scarce. However, results from studies such as this should help clinicians to differentiate among sildenafil, vardenafil, and tadalafil and to select the most appropriate for individual patients.编辑：bluelove

编辑： Zhu